Last reviewed · How we verify
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be performed at baseline and 7 years. At the end of the study, the cumulative rate of clinical hepatic hard endpoint will be calculated.
Details
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | UNKNOWN |
| Enrolment | 600 |
| Start date | 2016-01 |
| Completion | 2024-12 |
Conditions
- Chronic Hepatitis B
Interventions
- Nucleos(t)ide Analogues
Primary outcomes
- Cumulative rate of liver decompensation and/or hepatic carcinoma and/or liver related death — 10 years
Cumulative rate of liver decompensation (including ascites,hepatic encephalopathy,Gastrointestinal hemorrhage)，and/or hepatocellular carcinoma， and/or liver related death after 10 years of antiviral treatment
Countries
China